Navigation Links
Codexis Names Peter Strumph SVP, Commercial Operations
Date:6/28/2010

REDWOOD CITY, Calif., June 28 /PRNewswire-FirstCall/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Peter Strumph has joined the company as Senior Vice President, Commercial Operations, a new position.  Mr. Strumph will be responsible for Codexis pharmaceutical product management and manufacturing operations worldwide.  He will report to Joseph Sarret, M.D., Chief Business Officer and President, Pharmaceutical Services and Enzyme Products.  

Mr. Strumph joins Codexis with twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry. He was Chief Executive Officer of Nile Therapeutics, a cardiovascular company, from 2007-2009.  Previously, he held operations leadership positions for ten years at CV Therapeutics, most recently serving as Senior Vice President, Operations.  At CVT, he oversaw all CMC (chemistry, manufacturing and controls), quality and operations functions. He also held senior operations and manufacturing management roles at Biogen, and staff and manufacturing roles at Bio-Rad Laboratories and Bayer Pharmaceuticals.  Mr. Strumph holds a Bachelor's degree in Systems Science and Engineering and an MBA from the University of Pennsylvania.  

"We are very pleased to welcome Peter Strumph to our management team," Dr. Sarret said.  "He brings Codexis extensive manufacturing management experience, with a focus on commercializing pharmaceuticals products. His breadth of experience in managing successful global pharmaceuticals operations will enable us to better serve our expanding customer base."

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. 

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Derick Sutton, derick.sutton@codexis.com, 650-421-8130


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
2. Codexis, Inc. Announces Pricing of Initial Public Offering
3. Codexis Expands Pharmaceutical Manufacturing Partnerships
4. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Codexis Expands Collaboration with Teva
6. Codexis Names Fernando Valle Research Fellow
7. Gentris Corporation Names New Chief Executive Officer
8. Medical Device and Diagnostic Industry Names Envoy Medical a Company to Watch
9. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
10. Aveta Inc. Names Josh Valdez President of MSO of Puerto Rico, Inc.
11. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):